AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tryptophan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2780 | 73-22-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.600 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.794 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.347 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 0.891 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 68.230 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 66.870 | % | High | 1 |
| herg | hERG pIC50 | 4.760 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.143 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.467 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 82.680 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SYK,TEK,TGFBR1 | 27 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,EIF2AK3,GRK2 | 5 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.459 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 2.317 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 84 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.867 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 80.870 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 0.991 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 82.550 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 81.260 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 826.038 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foetal growth restriction | 59.78 | 33.35 | 15 | 990 | 9365 | 90618077 |
| Vascular malformation | 53.91 | 33.35 | 9 | 996 | 743 | 90626699 |
| Paranasal cyst | 53.24 | 33.35 | 9 | 996 | 801 | 90626641 |
| Mastoiditis | 46.73 | 33.35 | 9 | 996 | 1661 | 90625781 |
| Infantile apnoea | 42.68 | 33.35 | 8 | 997 | 1279 | 90626163 |
| Selective eating disorder | 38.95 | 33.35 | 8 | 997 | 2045 | 90625397 |
| Otitis media | 35.47 | 33.35 | 9 | 996 | 5861 | 90621581 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Genital hypoaesthesia | 40.74 | 32.41 | 6 | 433 | 237 | 42620659 |
| Ejaculation failure | 39.93 | 32.41 | 7 | 432 | 834 | 42620062 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bronchial hyperreactivity | 61.34 | 28.25 | 13 | 1330 | 3531 | 110584425 |
| Vascular malformation | 59.24 | 28.25 | 10 | 1333 | 804 | 110587152 |
| Paranasal cyst | 58.19 | 28.25 | 10 | 1333 | 894 | 110587062 |
| Breast disorder | 54.74 | 28.25 | 11 | 1332 | 2303 | 110585653 |
| Mastoiditis | 47.61 | 28.25 | 10 | 1333 | 2601 | 110585355 |
| Serotonin syndrome | 44.07 | 28.25 | 19 | 1324 | 59134 | 110528822 |
| Genital hypoaesthesia | 40.46 | 28.25 | 6 | 1337 | 209 | 110587747 |
| Otitis media | 37.15 | 28.25 | 10 | 1333 | 7466 | 110580490 |
| Ejaculation failure | 36.92 | 28.25 | 6 | 1337 | 382 | 110587574 |
| Multiple drug therapy | 31.87 | 28.25 | 9 | 1334 | 8005 | 110579951 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06AX02 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants |
| MeSH PA | D000928 | Antidepressive Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D018687 | Antidepressive Agents, Second-Generation |
| CHEBI has role | CHEBI:27027 | micronutrient |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:50733 | nutraceutical |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:75772 | <em>Saccharomyces cerevisiae </em> metabolite |
| CHEBI has role | CHEBI:76924 | plant metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:83056 | <em>Daphnia magna</em> metabolite |
Related Drugs by ATC class:
N06AX Other antidepressants 28 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Classical phenylketonuria | contraindication | 7573000 | |
| Depressive disorder | contraindication | 35489007 | |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Schizophrenia | contraindication | 58214004 | DOID:5419 |
| Autoimmune disease | contraindication | 85828009 | |
| Eosinophilia myalgia syndrome | contraindication | 95416007 | DOID:998 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.23 | acidic |
| pKa2 | 13.4 | acidic |
| pKa3 | 9.51 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Extracellular calcium-sensing receptor | GPCR | ALLOSTERIC MODULATOR | Kd | 4.40 | IUPHAR | ||||
| Myeloperoxidase | Enzyme | IC50 | 5.65 | CHEMBL | |||||
| Probable G-protein coupled receptor 139 | GPCR | AGONIST | IC50 | 4.59 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4029345 | VUID |
| N0000180301 | NUI |
| 4018677 | VANDF |
| 4029345 | VANDF |
| C0041249 | UMLSCUI |
| CHEBI:16828 | CHEBI |
| TRP | PDB_CHEM_ID |
| CHEMBL54976 | ChEMBL_ID |
| DB00150 | DRUGBANK_ID |
| D014364 | MESH_DESCRIPTOR_UI |
| 6305 | PUBCHEM_CID |
| 6173 | INN_ID |
| 8DUH1N11BX | UNII |
| 10898 | RXNORM |
| 12547 | MMSL |
| 237270 | MMSL |
| 48867 | MMSL |
| NOCODE | MMSL |
| d04732 | MMSL |
| 001438 | NDDF |
| 108952000 | SNOMEDCT_US |
| 54821000 | SNOMEDCT_US |
| 717 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.20 g | INTRAVENOUS | NDA | 23 sections |
| Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 250 mg | INTRAVENOUS | ANDA | 20 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 144 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION | 144 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 144 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 144 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 108 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0338-0202 | INJECTION | 144 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0338-0206 | INJECTION | 144 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0338-0210 | INJECTION | 144 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0338-0214 | INJECTION | 144 mg | INTRAVENOUS | NDA | 20 sections |
| ProSol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0499 | INJECTION, SOLUTION | 320 mg | INTRAVENOUS | NDA | 21 sections |
| Clinisol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0502 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | ANDA | 18 sections |
| Travasol | HUMAN PRESCRIPTION DRUG LABEL | 15 | 0338-0644 | INJECTION | 180 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1089 | INJECTION | 77 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1091 | INJECTION | 77 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1099 | INJECTION | 90 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1101 | INJECTION | 90 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1113 | INJECTION | 77 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1115 | INJECTION | 77 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1123 | INJECTION | 90 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1125 | INJECTION | 90 mg | INTRAVENOUS | NDA | 20 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1130 | INJECTION, SOLUTION | 0.20 g | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1131 | INJECTION, SOLUTION | 0.12 g | INTRAVENOUS | ANDA | 15 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1133 | INJECTION | 77 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1134 | INJECTION | 77 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1137 | INJECTION | 90 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1138 | INJECTION | 90 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1142 | INJECTION | 50 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1144 | INJECTION | 77 mg | INTRAVENOUS | NDA | 20 sections |